UniProt O00255
Menin (O00255)
Menin (UniProt O00255): 65 experimental structures on GenesisL1, 19 ligands bound, 17 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- O00255
- Protein
- Menin
- Experimental structures
- 65
- Predicted models
- 0
- Ligands
- 19
- Pockets
- 17 · 6 records with a druggable one
Structures
65 records of O00255 in the MolNFT archive: 65 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3U84 | Crystal Structure of Human Menin | x-ray diffraction | A, B | — | — |
| 3U84 | Crystal structure of human menin | x-ray diffraction | A, B | — | — |
| 3U85 | Crystal structure of human menin in complex with MLL1 | x-ray diffraction | A | — | — |
| 3U85 | Crystal structure of human menin in complex with MLL1 | x-ray diffraction | A | — | — |
| 3U86 | Crystal structure of human menin in complex with JunD | x-ray diffraction | A | — | — |
| 3U86 | Crystal structure of human menin in complex with jund | x-ray diffraction | A | — | — |
| 3U88 | Crystal structure of human menin in complex with MLL1 and LEDGF | x-ray diffraction | A, B | — | — |
| 3U88 | Crystal structure of human menin in complex with MLL1 and ledgf | x-ray diffraction | A, B | — | — |
| 4GPQ | Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in… | x-ray diffraction | A | — | — |
| 4GPQ | Structural insights into inhibition of the bivalent menin-mll interaction by small molecules in… | x-ray diffraction | A | — | — |
| 4GQ3 | Human menin with bound inhibitor MI-2 | x-ray diffraction | A | — | — |
| 4GQ3 | Human menin with bound inhibitor mi-2 | x-ray diffraction | A | — | — |
| 4GQ4 | Human menin with bound inhibitor MI-2-2 | x-ray diffraction | A | — | — |
| 4GQ4 | Human menin with bound inhibitor mi-2-2 | x-ray diffraction | A | — | — |
| 4GQ6 | Human menin in complex with MLL peptide | x-ray diffraction | A | — | — |
| 4GQ6 | Human menin in complex with mll peptide | x-ray diffraction | A | — | — |
| 4I80 | Crystal structure of human menin in complex with a high-affinity macrocyclic peptidomimetics | x-ray diffraction | A | — | — |
| 4I80 | Crystal structure of human menin in complex with a high-affinity macrocyclic peptidomimetics | x-ray diffraction | A | — | — |
| 4OG3 | Human menin with bound inhibitor MIV-3R | x-ray diffraction | A | — | — |
| 4OG3 | Human menin with bound inhibitor miv-3R | x-ray diffraction | A | — | — |
| 4OG4 | Human menin with bound inhibitor MIV-3S | x-ray diffraction | A | — | — |
| 4OG4 | Human menin with bound inhibitor miv-3S | x-ray diffraction | A | — | — |
| 4OG5 | Human menin with bound inhibitor MIV-5 | x-ray diffraction | A | — | — |
| 4OG5 | Human menin with bound inhibitor miv-5 | x-ray diffraction | A | — | — |
| 4OG6 | Human menin with bound inhibitor MIV-4 | x-ray diffraction | A | — | — |
| 4OG6 | Human menin with bound inhibitor miv-4 | x-ray diffraction | A | — | — |
| 4OG7 | Human menin with bound inhibitor MIV-7 | x-ray diffraction | A | — | — |
| 4OG7 | Human menin with bound inhibitor miv-7 | x-ray diffraction | A | — | — |
| 4OG8 | Human menin with bound inhibitor MIV-6R | x-ray diffraction | A | — | — |
| 4OG8 | Human menin with bound inhibitor miv-6R | x-ray diffraction | A | — | — |
| 4X5Y | Menin in complex with MI-503 | x-ray diffraction | A | — | — |
| 4X5Y | Menin in complex with mi-503 | x-ray diffraction | A | — | — |
| 4X5Z | menin in complex with MI-136 | x-ray diffraction | A | — | — |
| 4X5Z | Menin in complex with mi-136 | x-ray diffraction | A | — | — |
| 5DB0 | Menin in complex with MI-352 | x-ray diffraction | A | SO4, 58P, 6E6 | 4 (best 0.62) |
| 5DB0 | Menin in complex with mi-352 | x-ray diffraction | A | — | — |
| 5DB1 | Menin in complex with MI-336 | x-ray diffraction | A | 58O, SO4 | 2 (best 0.65) |
| 5DB1 | Menin in complex with mi-336 | x-ray diffraction | A | — | — |
| 5DB2 | Menin in complex with MI-389 | x-ray diffraction | A | SO4 | — |
| 5DB2 | Menin in complex with mi-389 | x-ray diffraction | A | — | — |
| 5DB3 | Menin in complex with MI-574 | x-ray diffraction | A | SO4, 58Q | 4 (best 0.64) |
| 5DB3 | Menin in complex with mi-574 | x-ray diffraction | A | — | — |
| 5DD9 | Menin in complex with MI-326 | x-ray diffraction | A | 59K, SO4 | 2 (best 0.62) |
| 5DD9 | Menin in complex with mi-326 | x-ray diffraction | A | — | — |
| 5DDA | Menin in complex with MI-333 | x-ray diffraction | A | 59M, SO4 | — |
| 5DDA | Menin in complex with mi-333 | x-ray diffraction | A | — | — |
| 5DDB | Menin in complex with mi-319 | x-ray diffraction | A | — | — |
| 5DDC | Menin in complex with MI-2-3 | x-ray diffraction | A | 59V | — |
| 5DDC | Menin in complex with mi-2-3 | x-ray diffraction | A | — | — |
| 5DDD | Menin in complex with mi-836 | x-ray diffraction | A | — | — |
| 5DDE | Menin in complex with mi-859 | x-ray diffraction | A | — | — |
| 5DDF | Menin in complex with MI-273 | x-ray diffraction | A | 5A1, SO4 | — |
| 5DDF | Menin in complex with mi-273 | x-ray diffraction | A | — | — |
| 6B41 | Menin bound to M-525 | x-ray diffraction | A | CJV, 7PR | — |
| 6BXH | Menin in complex with mi-853 | x-ray diffraction | A | SO4, EE7 | — |
| 6BY8 | Menin in complex with MI-1482 | x-ray diffraction | A | FNV, SO4 | 2 (best 0.63) |
| 6BY8 | Menin in complex with mi-1482 | x-ray diffraction | A | FNV, SO4 | — |
| 6E1A | Menin bound to M-89 | x-ray diffraction | A | HL7, 7PR | — |
| 6O5I | Menin in complex with mi-3454 | x-ray diffraction | A | LMY, SO4 | — |
| 6PKC | Inhibition of human menin by vtp-50469 | x-ray diffraction | A, B | OP4 | — |
5 records more on the page itself.
Ligands
- SO4 · Sulfate ion · in 11 records
- 7PR · praseodymium triacetate · in 5 records
- 7MM · Methyl [(1S,2R)-2-{(1S)-2-(azetidin-1-yl)-1-(3-fluorophenyl)-1-[1-({1-[4-({1-[4-(piperidin-1-yl) butanoyl]azetidin-3-yl}sulfonyl)phenyl]azetidin-3-yl}methyl)piperidin-4-yl]ethyl}cyclopentyl]carbamate · in 2 records
- FNV · 4-methyl-1-{[(2R)-5-oxomorpholin-2-yl]methyl}-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile · in 2 records
- 58O · 6-methoxy-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile · in 1 record
- 58P · 1-[(2S)-2,3-dihydroxypropyl]-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1 H-indole-2-carbonitrile · in 1 record
- 58Q · 6-methoxy-4-methyl-1-(1H-pyrazol-4-ylmethyl)-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile · in 1 record
- 59K · 4-[4-(5-methyl-1,3,4-thiadiazol-2-yl)piperazin-1-yl]-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine · in 1 record
- 59M · 4-{4-[5-(fluoromethyl)-1,3,4-thiadiazol-2-yl]piperazin-1-yl}-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine · in 1 record
- 59V · 6-(2,2,2-trifluoroethyl)-4-{4-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]piperazin-1-yl}thieno[2,3-d]pyrimidine · in 1 record
- 5A1 · 4-[4-(5,5-dimethyl-4,5-dihydro-1,3-thiazol-2-yl)piperazin-1-yl]-6-(pentafluoroethyl)thieno[2,3-d]pyrimidine · in 1 record
- 6E6 · 1-[(2R)-2,3-dihydroxypropyl]-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile · in 1 record
- CJV · Methyl {(1S,2R)-2-[(S)-cyano[1-({1-[4-({1-[4-(dimethylamino)butanoyl]azetidin-3-yl}sulfonyl) phenyl]azetidin-3-yl}methyl)piperidin-4-yl](3-fluorophenyl)methyl]cyclopentyl}carbamate · in 1 record
- EE7 · 1-{2-[4-(fluoroacetyl)piperazin-1-yl]ethyl}-4-methyl-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}piperidin-1-yl)methyl]-1H-indole-2-carbonitrile · in 1 record
- HL7 · (1S,2R)-2-[(4S)-2-methyl-4-{1-[(1-{4-[(pyridin-4-yl) sulfonyl]phenyl}azetidin-3-yl)methyl]piperidin-4-yl}-1,2,3,4-tetrahydroisoquinolin-4-yl]cyclopentyl methylcarbamate · in 1 record
- LMY · ~{N}-[3-[[2-cyano-4-methyl-5-[[4-[[2-(methylamino)-6-[2,2,2-tris(fluoranyl)ethyl]thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]indol-1-yl]methyl]-1-bicyclo[1.1.1]pentanyl]methanamide · in 1 record
- OP4 · 5-fluoro-2-({4-[7-({trans-4-[(methylsulfonyl) amino]cyclohexyl}methyl)-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl}oxy)-N,N-di(propan-2-yl)benzamide · in 1 record
- V6K · (~{E})-2-cyano-3-(4-hydroxyphenyl)-~{N}-(2-morpholin-4-ylethyl)prop-2-enamide · in 1 record
- YQV · Methyl {(1S,2R)-2-[(1S)-2-(azetidin-1-yl)-1-(3-fluorophenyl)-1-{1-[(3-methoxy-1-{4-[(1S,4S)-5-propanoyl-2,5-diazabicyclo[2.2.1]heptane-2-sulfonyl]phenyl}azetidin-3-yl)methyl]piperidin-4-yl}ethyl]cyclopentyl}carbamate · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.